Table 2.
Overview of agents
| Class | Subtype | Examples | Substrate | Primary use | Ex/Em | Turn-on/shift | Clinical | Modality | Limitations |
|---|---|---|---|---|---|---|---|---|---|
| Genetic tags | GFP | eGFP | NA | Fusion, reporter | 484/507 | Yes | No | IVM | Limited to proteins; no human use |
| RFP | mCherry | NA | Fusion, reporter | 587/610 | Yes | No | IVM | lower QY compared to GFP | |
| mRaspberry | NA | Fusion, reporter | 598/625 | Yes | No | IVM, FMT | lower QY compared to GFP | ||
| Katushka | NA | Fusion, reporter | 588/635 | Yes | No | IVM, FMT | lower QY compared to GFP | ||
| IFP | Biliverdin | Fusion, reporter | 684/708 | No | IVM, FMT | Emerging | |||
| Photo- conversion | Dendra | NA | Cytoplasmic, | 490/507 green | No | IVM | No human use | ||
| Cell position | 553/573 red | ||||||||
| Luciferases | Firefly | Luciferin | Reporter | broad em | Yes | No | BLI | Limited to proteins; no human use | |
| Renilla | Coelenterazine | Reporter | broad em | Yes | No | BLI | Limited to proteins; no human use | ||
| Gausia | Coelenterazine | Reporter | broad em | Yes | No | BLI | Limited to proteins; no human use | ||
| Antibodies | IgG | EGFR | NA | Cell surface marker | TD | Possible | Yes | PET, IVM, FMT | Delivery barriers; limited efficacy in vivo |
| Her2/neu | NA | Cell surface marker | TD | Possible | Yes | PET, IVM, FMT | Delivery barriers; limited efficacy in vivo | ||
| Fragments | Fab | NA | Cell surface marker | TD | Possible | Yes | PET, IVM, FMT | Delivery barriers; kinetics | |
| Diabody | NA | Cell surface marker | TD | Possible | Yes | PET, IVM, FMT | Delivery barriers; kinetics | ||
| Minibody | NA | Cell surface marker | TD | Possible | Yes | PET, IVM, FMT | Delivery barriers; kinetics | ||
| Small molecules | Metabolites | FDG, FLT, acetate | NA | Metabolism | TD | No | Yes | PET | Limited number agents |
| Steroids | NA | Reporter | TD | No | Yes | PET | Limited number agents | ||
| Hyperpolarized Molecules | NA | Metabolism | — | — | Yes | MRI | Time limitation | ||
| Drugs | Taxol-NBD | NA | Intracellular targets | TD | Possible | No | PET, IVM, FMT | Limited number of high affinity agents | |
| Prodrugs | Cathepsins, luminol | NA | Enzymes | TD | Yes | Yes | FMT, BLI | Limited number of high affinity agents | |
| Peptides | RGD, collagen | NA | Receptors | TD | No | Yes | PET, IVM, FMT | Limited number of high affinity agents | |
| Tags | CFSE, VT680 | NA | Cell tags | TD | Yes | No | IVM, FMT | Ex vivo labeling | |
| Cy dyes | NA | Generic labeling | TD | Yes | Planned | IVM, FMT | |||
| Environment | pH | NA | Hypoxia, endosomes | TD | Yes | No | IVM, FMT | Limited number of high affinity agents | |
| Nanotechnology | Q-dot | CdSe | NA | Cell surface marker | TD | Yes | No | IVM, FMT | Possible delivery barriers |
| Magnetic | MION | NA | Macrophages | TD | DMR | Yes | MRI | Possible delivery barriers | |
| CLIO | NA | Cell surface marker | TD | DMR | No | MRI | Experimental use only | ||
| Ferumoxytol | NA | Macrophages | TD | DMR | Yes | MRI | Possible delivery barriers | ||
| Polymers | Prosense | NA | Proteasses | TD | Yes | Planned | FMT | Possible delivery barriers | |
| Angiosense | NA | Vascualrity | TD | No | No | FMT | Experimental use only | ||
| Bionano | Phage | NA | Cell surface marker | TD | No | No | FMT, MRI | Experimental use only | |
| Bioorthogonal | Staudinger | triarylphosphine | Azide | Proteins, carbohydrate | TD | No | No | IVM | Limited in vivo experience |
| 3,2 click | alkyne | Azide | Proteins | TD | No | No | FMT, IVM, PET | Limited in vivo experience; reaction slow | |
| 4,6 Click | Norbornene | Tetrazine | Many targets | TD | No | No | FMT, IVM, PET | Emerging | |
| TCO | Tetrazine | All targets | TD | Yes | Planned | FMT, IVM, PET | Emerging |
TD = depends on attached fluorochrome (VT, Alexa, Cy, etc.) or other tracer (18F, 11C).